Persistent tissue hypoperfusion improves risk stratification beyond vasopressor dose in refractory septic shock: a secondary analysis of the ANDROMEDA-SHOCK-2 trial.

Kattan E, Ospina-Tascón GA, Orozco N, Teboul JL, Melo P, Wendel-Garcia PD, Morales S, Amthauer M, Hunsicker O, Ibarra-Estrada M, Leone M, Khanna AK, Hamzaoui O, Messina A, Myatra SN, Ramasco F, Vieillard-Baron A, Putowski Z, Ferri G, Castro R, Biasi-Cavalcanti A, De Backer D, Bakker J, Hernandez G, ANDROMEDA-SHOCK-2 investigators, ANDROMEDA-Research Network

Open source

DOI: 10.1007/s00134-026-08551-x
Published: 2026 Jul 15
Container: Intensive care medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00134-026-08551-x,
  title = {Persistent tissue hypoperfusion improves risk stratification beyond vasopressor dose in refractory septic shock: a secondary analysis of the ANDROMEDA-SHOCK-2 trial.},
  author = {Kattan E and Ospina-Tascón GA and Orozco N and Teboul JL and Melo P and Wendel-Garcia PD and Morales S and Amthauer M and Hunsicker O and Ibarra-Estrada M and Leone M and Khanna AK and Hamzaoui O and Messina A and Myatra SN and Ramasco F and Vieillard-Baron A and Putowski Z and Ferri G and Castro R and Biasi-Cavalcanti A and De Backer D and Bakker J and Hernandez G and ANDROMEDA-SHOCK-2 investigators, ANDROMEDA-Research Network},
  year = {2026},
  journal = {Intensive care medicine},
  doi = {10.1007/s00134-026-08551-x},
  url = {https://doi.org/10.1007/s00134-026-08551-x}
}

RIS

TY  - JOUR
TI  - Persistent tissue hypoperfusion improves risk stratification beyond vasopressor dose in refractory septic shock: a secondary analysis of the ANDROMEDA-SHOCK-2 trial.
AU  - Kattan E
AU  - Ospina-Tascón GA
AU  - Orozco N
AU  - Teboul JL
AU  - Melo P
AU  - Wendel-Garcia PD
AU  - Morales S
AU  - Amthauer M
AU  - Hunsicker O
AU  - Ibarra-Estrada M
AU  - Leone M
AU  - Khanna AK
AU  - Hamzaoui O
AU  - Messina A
AU  - Myatra SN
AU  - Ramasco F
AU  - Vieillard-Baron A
AU  - Putowski Z
AU  - Ferri G
AU  - Castro R
AU  - Biasi-Cavalcanti A
AU  - De Backer D
AU  - Bakker J
AU  - Hernandez G
AU  - ANDROMEDA-SHOCK-2 investigators, ANDROMEDA-Research Network
PY  - 2026
JO  - Intensive care medicine
DO  - 10.1007/s00134-026-08551-x
UR  - https://doi.org/10.1007/s00134-026-08551-x
ER  -

APA

E, K., GA, O., N, O., JL, T., P, M., PD, W., S, M., M, A., O, H., M, I., M, L., AK, K., O, H., A, M., SN, M., F, R., A, V., Z, P., G, F., R, C., A, B., D, D. B., J, B., G, H., & Network, A. I. A. (2026). Persistent tissue hypoperfusion improves risk stratification beyond vasopressor dose in refractory septic shock: a secondary analysis of the ANDROMEDA-SHOCK-2 trial.. Intensive care medicine. https://doi.org/10.1007/s00134-026-08551-x

Source records

pubmed · retrieved 2026-09-25T10:59:21.746Z